Malaysia's Medicine Advertisement Board (MAB) — under the Medicines (Advertisement and Sale) Act 1956 and elaborated in the Pharmacy Act guidelines for healthcare facilities — strictly regulates what private healthcare clinics may say in their marketing material. The benchmarked B2C model used by Prenuvo, Ezra, Function Health and similar US-based providers is functionally illegal in Malaysia. This page documents how the AEVUM marketing site has been audited against the MAB rules, what was changed, and what remains for review by a Malaysian-registered healthcare lawyer prior to public launch.
"Mrs Tan from Bangsar said her scan saved her life" — not permitted, even if the testimonial is genuine and offered voluntarily.
Kim Kardashian-style celebrity recommendation of a clinical service. No celebrity may endorse a treatment or service.
"Our radiologists are the best in the region" / "world-renowned consultant" / "Dr X is internationally acclaimed". Listing names & basic qualifications for verification is allowed; framing as superior expertise is not.
"Our scan is 50% cheaper than Hospital X" / "We charge less than Mt Elizabeth". Even factually true comparisons are prohibited.
"First consultation free" / "Complimentary follow-up visit". Bundled inclusions inside a paid package are different and are permitted.
Catch-all clause. Includes "the most comprehensive scan in the region", "guaranteed early detection", "the only clinic that…".
"Our Comprehensive package: full-body MRI + 60-min consultation + bound report = RM 8,699." This is permitted. Itemised inclusions inside the bundle are permitted.
"15% off the Comprehensive package during Mother's Day week" / "Founders' Programme rate, valid Q3 2026 only" — explicit time-limited discounts on full bundled packages are permitted.
Listing the names, MMC registration numbers, and basic qualifications (MBBS, MMed, FRCR) of practitioners — required under Act 586 anyway. The line is between disclosure (permitted) and promotion (not).
"5,000 sq ft facility, three Siemens MAGNETOM magnets, RF-shielded suites, on-site emergency capability." Factual descriptions of facility, equipment, and technology are permitted in full.
Each violation identified, with the original phrasing, the MAB rule cited, the rewrite applied, and the reason. All seven violations have been fixed in the live site as of v0.5.
The public-facing AEVUM site that potential guests will visit. All consumer-facing copy here is subject to MAB review and has been audited above.
These are internal strategy and research panels. They contain inter-clinic price comparisons, pricing strategy analyses, and competitor positioning material. This content is appropriate inside an internal strategy document but must NOT be reused in any consumer-facing marketing. Pre-launch, these pages should be password-gated or removed from the public site.
Style exploration drafts kept for design-direction comparison. Pre-launch, these should be removed from the public site or moved to a password-protected staging URL. Re-audit any draft that becomes the live site.
Any future content added to the public AEVUM site must be re-audited under the same MAB framework before publication. The Bahasa Indonesia microsite is particularly sensitive — translation can introduce subtle promotional emphasis that the original English avoided.
The internal audit above is a starting point, not a substitute for legal opinion. Before the AEVUM site is published in production form (i.e. with real consultant names, in a way that constitutes "advertising" to the Malaysian public), this audit should be reviewed and signed off by Malaysian-registered legal counsel competent in healthcare advertising regulation.
Recommended additional checks the lawyer should perform: (1) confirm A-08 once consultant hires are finalised; (2) review every imported asset (photography, video) for incidental MAB exposure; (3) approve the launch press release and any paid-channel ad copy; (4) confirm the Bahasa Indonesia translation does not materially change the regulatory weight of any sentence.